Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Company Overview

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company developing prescription medicines designed to improve the safety of opioid pain treatment. The company focuses on technologies intended to reduce the potential for opioid abuse, misuse, and overdose while preserving analgesic activity.

Ensysce’s lead program is PF614, an investigational extended-release oxycodone prodrug being developed with its Trypsin-Activated Abuse Protection (TAAP) technology. The platform is designed to limit the release of active oxycodone when the product is manipulated for non-oral use. Ensysce has also been developing PF614-MPAR, a combination product intended to pair PF614 with an overdose-protection component.

The company’s pipeline is aimed primarily at the prescription pain-management market and reflects its broader focus on creating abuse-deterrent and overdose-resistant opioid formulations. Ensysce Biosciences is headquartered in San Diego, California, and its programs remain subject to clinical development and regulatory review.

Key Stats

• Today's Range: $0.44 to $0.46
• 50-Day Range: $0.25 to $0.52
• 52-Week Range: $0.23 to $2.75
• Volume: 494,514 shs
• Average Volume: 676,867 shs
• Market Capitalization: $8.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Ensysce Biosciences Stock Analysis - MarketRank™

Ensysce Biosciences scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Ensysce Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Ensysce Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ensysce Biosciences are expected to grow in the coming year, from ($1.09) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ensysce Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ensysce Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ensysce Biosciences has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.54% of the float of Ensysce Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Ensysce Biosciences has a short interest ratio ("days to cover") of 1.16, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ensysce Biosciences has recently increased by 25.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ensysce Biosciences does not currently pay a dividend.

Dividend Growth

Ensysce Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Ensysce Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

Search Interest

Only 3 people have searched for ENSC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.0 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $196,000.00 in company stock, which represents 2.1986% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Ensysce Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $196,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.80% of the stock of Ensysce Biosciences is held by insiders.

Percentage Held by Institutions

5.63% of the stock of Ensysce Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/18/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ENSC
• CIK: 1716947
• Web: ensysce.com
• Phone: 858-263-4196
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.18 million
• Net Margins: -280.53%
• Pretax Margin: -280.51%
• Return on Equity: -2,550.30%
• Return on Assets: -320.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.70
• Quick Ratio: 0.70

Sales & Book Value

• Annual Sales: $5.07 million
• Price / Sales: 1.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.63 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 19,460,000
• Free Float: 18,912,000
• Market Cap: $8.91 million
• Optionable: Not Optionable
• Beta: 0.97